We will generate stocks of influenza pandemic A/California/04/09 H1N1 (pH1N1) and A/Wyoming/3/03 H3N2 influenza A viruses as well as influenza B/Brisbane/60/08 mCherry-expressing viruses that will be used to optimize the performance of PRESCIENT (Aim 1), to test the working hypothesis that PRESCIENT can identify in a mixed population of individual human hybridoma cells neutralizing antibodies against pH1N1 virus (Aim 2) and to identify influenza A H1N1, H3N2; and B virus neutralizing antibodies from EBV-immortalized patient-derived B cells (Aim 3).

Our goal is to exploit under-utilized museum collections with molecular tools to understand the natural history of zoonotic pathogens transmitted by rodents. In AIM1 we will use a PCR-based method to identify rodents infected with human-parasitic schistosomes. In AIM2 we will use a sequence-capture array to identify individuals infected with major human pathogens that can describe the expansion and contraction of zoonoses across the landscape and through time.

To obtain funds for Ms. Angelica Olmo-Fontanez to cover her research in Aging and tuberculosis in Dr. Torrelles laboratory.

The proposed studies aimed at understanding the molecular mechanisms underlying B-cell dysfunction and developing novel immune modulation strategies to decrease inflammation and B-cell dysfunction could have a significant impact on the course of HIV infection, as well as a number of other autoimmune chronic inflammatory diseases associated with B-cell defects.

The goal of this research is to understand how the Rv2623 protein of Mycobacterium tuberculosis, the bacterial pathogen that causes tuberculosis, regulates growth of this bacterium in an infected person, including in the context of the development of a dormant/latent infection, with the ultimate goal of designing novel treatment for tuberculous infection.

The major goal of this project is to determine levels of anti-Ebola virus glycoprotein antibodies in nonhuman primates vaccinated off-site with anti-Ebola virus vaccines.

This is a multicenter, phase 3, double-blind, randomized, placebo-controlled study. Patients who qualify for study inclusion will be randomized in a 1:1:1 manner to receive MGL-3196 100 mg, MGL-3196 80 mg, or matching placebo given orally once daily in the morning for up to 54 months. If any patient has a Composite clinical outcome event on the Week 52 liver biopsy or any clinical composite event after Week 52 and prior to month 54 they will discontinue from the main study and will be allowed to participate in an open-label study on active treatment with MGL-3196.

The primary objective of this study is to demonstrate the long-term safety and efficacy of ozanimod for the treatment of subjects with moderate to severely active Crohn's disease (CD).

In 2017, an estimated 10 million people developed TB disease, demonstrating an urgent need for new approaches to therapy, including host-directed therapy (HDT), to halt infection and progression of active TB. To this end, the overall goal of our ongoing research program is to identify intracellular ?master regulators? of inflammation and metabolic intermediates that dictate human macrophage responses to Mycobacterium tuberculosis infection as a strategy to identify potential host cell targets for HDT.